| Grant number: | 04/14258-0 |
| Support Opportunities: | Research Grants - Innovative Research in Small Business - PIPE |
| Start date: | May 01, 2005 |
| End date: | April 30, 2008 |
| Field of knowledge: | Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology |
| Principal Investigator: | Andrea Sterman Heimann |
| Grantee: | Andrea Sterman Heimann |
| Company: | Proteimax Consultoria S/S Ltda |
Abstract
Receptors attached to the G (GPCRs) protein have shown themselves to be an interesting therapeutic target. Thirty-nine of the 100 most commonly used drugs in clinics act directly or indirectly through the activation or blocking of receptors of the GPCRs (Menzaghi et al. 2002) type. The production of antibodies which recognize a specific conformation of GPCRs (active or inactive) represents a new and powerful technique which may be used to examine the duration and extent of physiopathological stimuli directly, which is important for basic and clinical research. In addition, this technique could create a fast and cheap screening tool for the identification of drugs that are allosteric modulators of GPCRs, enabling the development of drugs (which could be of great therapeutic and economic value) with the power to activate or inhibit GPCRs in smaller doses. Proteimax, perceiving a great consumer market for antibodies with conformational specificity, intends to produce antibodies that recognize activated GPCRs, as well as normalizing antibodies for protein quantification tests, supplying a unique, high quality product for studies related to GPCRs. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |